share_log

Theriva Biologics To Discuss The Trial Design For VIRAGE - A Phase 2b Clinical Study Of Systemically Administered VCN-01 In Combination With Chemotherapy In Pancreatic Ductal Adenocarcinoma At The 2024 ASCO Annual Meeting

Theriva Biologics To Discuss The Trial Design For VIRAGE - A Phase 2b Clinical Study Of Systemically Administered VCN-01 In Combination With Chemotherapy In Pancreatic Ductal Adenocarcinoma At The 2024 ASCO Annual Meeting

Theriva Biologics 将在 2024 年 ASCO 年会上讨论 VIRAGE 的试验设计——一项针对胰腺导管腺癌的全身给药 VCN-01 联合化疗的 2b 期临床研究
Benzinga ·  04/25 08:34

Theriva Biologics (NYSE:TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that, based on the strength of the science and its relevance, VIRAGE - the Phase 2b randomized, open-label, placebo-controlled, multicenter clinical trial of systemically administered VCN-01 in combination with standard-of-care (SoC) chemotherapy (gemcitabine/nab-paclitaxel) as a first line therapy for patients with newly-diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC) - has been accepted for presentation as a trial-in-progress poster at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, IL, from May 31-June 4.

Theriva Biologics（纽约证券交易所代码：TOVX）是一家处于临床阶段的多元化公司，正在开发旨在治疗高未满足需求领域的癌症和相关疾病的疗法。该公司今天宣布，基于科学的力量及其相关性，VIRAGE——全身给药 VCN-01 与标准护理（SoC）化疗联合使用的 2b 期随机、开放标签、安慰剂对照的多中心临床试验（吉西他滨/nab-紫杉醇）作为新诊断的转移性胰腺导管腺癌（PDAC）患者的一线疗法-已获准在5月31日至6月4日在伊利诺伊州芝加哥举行的2024年美国临床肿瘤学会（ASCO）年会上作为试用海报展出。

ASCO Presentation Details

ASCO 演示详情

  • Title: VIRAGE: A Phase IIb, Open-label, Randomized Study of Nab-Paclitaxel and Gemcitabine plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer
  • Presenter: Dr. Rocío García-Carbonero
  • Session Title: Poster Session – Gastrointestinal Cancer: Gastroesophageal, Pancreatic, and Hepatobiliary
  • Poster Session Date and Time: 01 June 2024, 1:30 PM-4:30 PM US CDT
    • Abstract Number: TPS4210
  • 标题：VIRAGE：一项针对转移性胰腺癌患者的 Nab-Paclitaxel 和 Gemcitabine 加/减 VCN-01 的 IIb 期、开放标签、随机研究
  • 主持人：罗西奥·加西亚-卡博内罗博士
  • 会议标题：海报会议 — 胃肠道癌：胃食管、胰腺和肝胆癌
  • 海报发布会日期和时间：2024 年 6 月 1 日，美国中部夏令时间下午 1:30 至下午 4:30
    • 摘要编号：TPS4210
声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发